Paper
0
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Authors
Efstathios Kastritis,Giovanni Palladini
Monique Minnema,Ashutosh Wechalekar,Arnaud Jaccard,Hans Lee,Vaishali Sanchorawala,Simon Gibbs,Peter Mollee,Christopher Venner,Jin Lu,Stefan Schönland,Moshe Gatt,Kenshi Suzuki,Kihyun Kım,M. Cibeira,Meral Beksaç,Edward Libby,Jason Valent,Vânia Hungria,Sandy Wong,Michael Rosenzweig,Naresh Bumma,Antoine Huart,Meletios Dimopoulos,Divaya Bhutani,Adam Waxman,Stacey Goodman,Jeffrey Zonder,Selay Lam,Kevin Song,Timon Hansen,Morten Salomo,Wilfried Roeloffzen,Krzysztof Jamroziak,Fiona Kwok,Chihiro Shimazaki,Jin Kim,Edvan Crusoé,Tahamtan Ahmadi,Namphuong Tran,Xiang Qin,Sandra Vasey,Brenda Tromp,Jordan Schecter,Brendan Weiss,Sen Zhuang,Jessica Vermeulen,Giampaolo Merlini,Raymond Comenzo
+48 authors
,María-Teresa CibeiraPublished
Jun 30, 2021
Show more
Save
Tip0
TipSave
Abstract
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.